Mark L. Jacobson - 26 Feb 2026 Form 4 Insider Report for Axsome Therapeutics, Inc. (AXSM)

Signature
/s/ Mark Jacobson
Issuer symbol
AXSM
Transactions as of
26 Feb 2026
Net transactions value
-$5,626,163
Form type
4
Filing time
27 Feb 2026, 19:00:06 UTC
Previous filing
22 Sep 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Jacobson Mark L. Chief Operating Officer C/O AXSOME THERAPEUTICS, INC., ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK /s/ Mark Jacobson 27 Feb 2026 0001805812

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXSM Common Stock Options Exercise $100,827 +35,378 $2.85 35,378 26 Feb 2026 Direct F1, F2
transaction AXSM Common Stock Sale $5,726,991 -35,378 -100% $161.88 0 26 Feb 2026 Direct F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXSM Stock Option (Right to Buy) Options Exercise $0 -35,378 -100% $0.000000 0 26 Feb 2026 Common Stock 35,378 $2.85 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options.
F2 Such transaction was pursuant to a pre-approved 10b5-1 plan.
F3 Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
F4 Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $160.10 and $163.42.